Drug Profile
Research programme: alpha-7 nicotinic acetylcholine receptor agonists - Roche
Alternative Names: Nicotinic alpha-7 receptor agonists - Memory Pharmaceuticals/Roche; α7 nAChR agonists - Memory Pharmaceuticals/RocheLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Memory Pharmaceuticals
- Developer Roche
- Class
- Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists; Nicotinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Schizophrenia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Schizophrenia in USA (PO)
- 05 Sep 2007 Preclinical development is ongoing